COPEGUS

LOE Approaching

ribavirin

Roche

NDAORALTABLETPriority Review

Approved

Dec 2002

Lifecycle

LOE Approaching

Competitive Pressure

30/100

Clinical Trials

Mechanism of Action

Mechanism of Action In cell cultures the inhibitory activity of ribavirin for respiratory syncytial virus (RSV) is selective. The mechanism of action is unknown. Reversal of the in vitro antiviral activity by guanosine or xanthosine suggests ribavirin may act as an analogue of these cellular…

Indications (7)

hospitalized infants young children with severe lower respiratory tract infections due to RSV VIRAZOLE precipitation ventilator malfunction heated wire tubing two bacterial filters connected in series in the expiratory limb of the ventilator (with filter changes every 4 hours)water column pressure release valves to monitor internal ventilator pressures were used in connecting ventilator circuits to the SPAG-2

Clinical Trials (5)

NCT04907682Phase 2Completed

Pharmacokinetics, Tolerability and Safety of Favipiravir Compared to Ribavirin for the Treatment of Lassa Fever

Started Jul 2021

40 enrolled

Lassa Fever

NCT04774107Phase 1Completed

The Pharmacokinetics of P1101 + Ribavirin in Interferon Treatment-Naïve Subjects With Chronic Hepatitis C Virus (HCV) Genotype 2 Infection

Started Nov 2020

17 enrolled

Hepatitis C, Chronic

NCT03889106N/ATerminated

Cardiovascular Function and Ribavirin Pharmacokinetics and Pharmacodynamics in Patients With Lassa Fever

Started Mar 2019

2 enrolled

Lassa Fever

NCT03053180N/ACompleted

Real World Evidence of the Effectiveness of Paritaprevir/Ritonavir (r) - Ombitasvir, + Dasabuvir Without Ribavirin in Participants With Chronic Hepatitis C and Compensated Liver Cirrhosis in the Russian Federation

Started Mar 2017

60 enrolled

Chronic Hepatitis C

NCT02851069N/ACompleted

Real World Evidence of the Effectiveness of Paritaprevir/r - Ombitasvir, ± Dasabuvir, ± Ribavirin in Patients With Chronic Hepatitis C in Colombia

Started Feb 2017

66 enrolled

Chronic Hepatitis C

Company